Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | recruiting | Phase 2 / Phase 3 | 534 | Blueprint Medicines CorporationINDUSTRY | 23 | Sep 23, 2026 |
| clinicaltrials |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | recruiting | Phase 2 | 140 | Cogent Biosciences, Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00449748 | Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | completed | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03731260 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | active not recruiting | Phase 2 | 251 | Blueprint Medicines CorporationINDUSTRY | 13 | Sep 23, 2025 | clinicaltrials |
| NCT01701843 | Cromoglicate in Mastocytosis | terminated | Phase 2 | 7 | LEO PharmaINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03770273 | Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | completed | Phase 2 | 21 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT04846348 | Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis | terminated | Phase 2 | 1 | Joseph ButterfieldOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05084872 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients(HCQMa) | unknown | Phase 2 / Phase 3 | 30 | University Hospital, ToulouseOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00831974 | Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis | completed | Phase 2 | 23 | AB ScienceINDUSTRY | 0 | Dec 11, 2018 | clinicaltrials |
| NCT01266369 | Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation | completed | Phase 2 | 21 | AB ScienceINDUSTRY | 0 | Dec 10, 2018 | clinicaltrials |
| NCT00233454 | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | completed | Phase 2 | 26 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT02415608 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | terminated | Phase 2 | 4 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00186628 | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | completed | Phase 2 | 36 | Stanford UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00006413 | Stem Cell Transplantation to Treat Systemic Mastocytosis | completed | Phase 2 | 25 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01481909 | Study on Mastocytosis for Rupatadine Treatment(SMART) | completed | Phase 2 / Phase 3 | 30 | Marcus MaurerOTHER | 1 | Nov 3, 2016 | clinicaltrials |
| NCT02478957 | Treatment of Indolent Systemic Mastocytosis With PA101 | completed | Phase 2 | 41 | Patara PharmaINDUSTRY | 5 | Sep 29, 2016 | clinicaltrials |
| NCT01602939 | Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis | unknown | Phase 2 / Phase 3 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01333293 | The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients(XOLMA) | completed | Phase 2 / Phase 3 | 17 | University of ZurichOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01920204 | Midostaurin in Indolent Systemic Mastocytosis | unknown | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00493129 | Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00918931 | Obatoclax for Systemic Mastocytosis | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00979160 | Evaluation of Response of Dasatinib to Treat Mastocytosis | unknown | Phase 2 | 30 | Federico II UniversityOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00457288 | Efficacy and Safety of TF002 in Cutaneous Mastocytosis | completed | Phase 2 | 30 | JADO Technologies GmbHINDUSTRY | 1 | Nov 12, 2007 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials